ALS treatment Relyvrio fails trial, may be withdrawn from market
Relyvrio (sodium phenylbutyrate and taurursodiol), an approved treatment for people with amyotrophic lateral sclerosis (ALS), has failed to…
Articles by Marisa Wexler, MS
MDA 2024: Blood biomarkers may help predict ALS progression rates
New data show that blood-based measures, including levels of markers of nerve damage and chemical DNA modifications, can help predict…
MDA 2024: Planned Phase 3b trial aims to support NurOwn’s approval
Note: This story was updated March 6, 2024, to correct the poster was presented by Brainstorm’s executive vice president…
MDA 2024: Most patients don’t get recommended treatments for ALS
While the most recent guidelines for treating amyotrophic lateral sclerosis (ALS) recommend that patients receive three available treatments together,…
Health Canada rejects masitinib application; reconsideration sought
Health Canada has issued a notice of noncompliance-withdrawal saying it won’t approve the oral therapy masitinib as an add-on…
Experimental gene therapy CTx1000 extends survival in mice
An experimental gene therapy called CTx1000, which is designed to reduce toxic buildups of the protein TDP-43 in nerve cells,…
Potential ALS treatment ATH-1105 due to enter clinical testing this year
Treatment with the experimental oral therapy ATH-1105 significantly reduced nerve damage, improved motor function, and prolonged survival in…
Blocking MAP4Ks proteins extends survival in ALS mouse model
A new compound that significantly extended survival in a mouse model of amyotrophic lateral sclerosis (ALS)…
TDP-43 deficiency leads to changes in physical structures of cell DNA
Reduced activity of the TDP-43 protein, a hallmark of amyotrophic lateral sclerosis (ALS), leads to changes in the DNA…
Novel AI-powered platform aims to help ALS patients to communicate
Researchers have unveiled a new AI-powered avatar platform — one making use of artificial intelligence (AI) technology — that aims…